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1506Available online 3 September 2020Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of
neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new
personalized therapies for a subset of patients with sarcoma in the form of tropomyosin receptor kinase (TRK)
inhibitors. NTRK gene rearrangements and fusion transcripts can be detected with different molecular pathology
techniques, while TRK protein expression can be demonstrated with immunohistochemistry. The rarity and
diagnostic complexity of NTRK gene fusions raise a number of questions and challenges for clinicians. To address
these challenges, the World Sarcoma Network convened two meetings of expert adult oncologists and pathologists
and subsequently developed this article to provide practical guidance on the management of patients with sarcoma
harboring NTRK gene fusions. We propose a diagnostic strategy that considers disease stage and histologic and
molecular subtypes to facilitate routine testing for TRK expression and subsequent testing for NTRK gene fusions.
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G. D. Demetri et al. Annals of OncologyINTRODUCTION
Sarcomas are a heterogeneous group of malignancies that
exhibit mesenchymal lineage differentiation. They arise in
either soft tissue (w80%) or bone (w20%) and comprise
w70 malignant subtypes (per World Health Organization
classification), each with distinct underlying biology and
clinical behavior.1 Sarcomas account for approximately 1%
of all adult cancers and 20% of all pediatric solid tumors.2
Complete resection (with or without radiation and/or
chemotherapy) forms the mainstay of curative management
for most subtypes in the localized setting. For patients
diagnosed with locally advanced or metastatic disease, or
those with disease recurrence following surgery, treatment
options include systemic therapy and potential local ap-
proaches such as radiation, isolated limb perfusion, surgery,
and ablation techniques.3 The median overall survival of
patients with advanced soft tissue sarcomas is approxi-
mately 20 months, with most patients deriving only tran-
sient benefit from palliative chemotherapy.4,5 Therefore,
there is a clear unmet need for more effective systemic
therapies for patients with advanced/metastatic sarcomas.
As our understanding of the molecular basis of tumori-
genesis has improved with advances in diagnostic technol-
ogy, precision oncology approaches to the treatment of
sarcomas have emerged. A classic example of this is
mutational profiling of KIT, PDGFRA, and other genes to
predict sensitivity of gastrointestinal stromal tumors (GISTs)
to imatinib and other KIT/PDGFRA tyrosine kinase in-
hibitors.6-11 More recently, the discovery of neurotrophic
tyrosine receptor kinase (NTRK) gene fusions as pan-tumor
oncogenic drivers has provided new precision medicine-
based treatment options for a subset of patients with sar-
coma.12 The rarity and diagnostic complexity of this
particular biomarker raise a number of questions and
challenges for clinicians.
To address these issues, the World Sarcoma Network, a
think tank gathering national and international sarcoma
groups for the past 10 years, convened two consensus
meetings of expert adult oncologists and pathologists to
discuss diagnostic challenges and propose a diagnostic
strategy in this area.We subsequently developed this article
to provide practical guidance on how to optimally integrate
the NTRK gene fusion biomarker into the clinical manage-
ment of patients with sarcoma.NTRK GENE FUSIONS
The NTRK genes NTRK1 (chromosome 1q23.1), NTRK2
(chromosome 9q21.33), and NTRK3 (chromosome 15q25.3)
are typically involved in normal neuronal development and
encode the tropomyosin receptor kinase (TRK) proteins,
traditionally known as TRKA, TRKB, and TRKC, respec-
tively.12,13 Wild-type TRK proteins are activated through
oligomerization mediated by the binding of neurotrophin
ligands.14 Subsequent downstream signaling contributes to
central nervous system (CNS) development and regulation
of appetite, body weight, memory, mood, movement, pain,
and proprioception.15-20Volume 31 - Issue 11 - 2020NTRK gene fusions have been identified in a diverse
range of adult and pediatric tumor types.12 These fusions
result from inter- or intra-chromosomal rearrangements
leading to juxtaposition of the 30 region of an NTRK gene
(encoding the full kinase domain) with the 50 region of a
partner gene (encoding an oligomerization or other protein-
association domain), ultimately producing a constitutively
active TRK fusion protein.21 Fusions involving NTRK gene 50
regions have also been reported, although the pathoge-
nicity of these is unclear.22 In addition to fusions, NTRK gene
point mutations and amplifications have been identified in a
variety of different cancer types; however, roles for these
aberrations in tumorigenesis have not been established.22
While rare in most common tumor types (e.g. lung and
colorectal cancers), NTRK gene fusions are reported to be
recurrent in a subset of rare tumor types (e.g. secretory
carcinoma of the salivary gland, secretory carcinoma of the
breast, congenital mesoblastic nephroma, pediatric mela-
noma, and infantile fibrosarcoma).21,23,24 One of the first
discovered and most well characterized fusions, ETV6-
NTRK3, resulting from a t(12;15)(p13;q25) translocation, is
present in >90% of infantile fibrosarcomas.25,26 By contrast,
NTRK fusions have been identified in other adult and pe-
diatric sarcomas at a frequency of <1%.23,27,28 Recent
studies investigating NTRK fusions among mesenchymal
neoplasms have identified a number of emerging new soft
tissue tumor entities displaying various phenotypes, which
resemble lipofibromatosis, fibrosarcoma, and malignant
peripheral nerve sheath tumors (Table 1). A significant
number of these NTRK fusion-positive tumors show co-
expression of S100 protein and CD34, while the rest have
a nonspecific immunophenotype.27,29-32 The published
literature on NTRK gene fusion frequency in sarcomas is
limited and more data are needed.
TARGETED THERAPY FOR TRK FUSION CANCERS
NTRK gene fusions (but not other NTRK alterations) appear
to be primary oncogenic drivers in the tumors that harbor
them. The encoded fusion proteins feature constitutive
tyrosine kinase activity that may be targeted clinically with a
number of agents that are either approved or in
development.12,33Larotrectinib
Larotrectinib is a first-in-class, ATP-competitive, small-
molecule inhibitor of TRK. It is highly potent, with IC50
values in the range of 6.5-10.6 nM, and highly selective for
TRKA, B, and C, with binding affinities over 100-fold greater
than for a panel of other kinases.24,34,35 Larotrectinib is
approved by the US Food and Drug Administration (FDA)
and European Medicines Agency (EMA) for use in adult and
pediatric patients with solid tumors harboring an NTRK
gene fusion who have disease that is locally advanced or
metastatic, or where surgery is likely to result in severe
morbidity, and who have no satisfactory treatment
options.36,37 Patients with a known resistance mutation are
not indicated for larotrectinib treatment.https://doi.org/10.1016/j.annonc.2020.08.2232 1507
Table 1. Frequency of NTRK gene fusions identified in sarcomas
Study Testing method Proportion of
NTRK
fusions identified
NTRK fusion-positive sarcoma subtypes NTRK genes and fusion
partners involved
Agaram et al.29 FISH, RNA MPS 71% (10/14) Lipofibromatosis-like neural tumor 1 TPR-NTRK1
1 TPM3-NTRK1
4 LMNA-NTRK1
Bourgeois et al.68 RT-PCR 91% (10/11) IFS ETV6-NTRK3
Bui et al.69 Targeted DNA MPS 0.7% (1/152) Myopericytoma NR
Chang et al.70 Targeted RNA MPS 33% (3/9) IMT ETV6-NTRK3
Chmielecki et al.71 Targeted RNA MPS 1% (4/324) IFS (n ¼ 2), assorted soft tissue sarcoma (n ¼ 1),
hemangioma (n ¼ 1), bone sarcoma (n ¼ 1)
SQSTM1-NTRK1 (n ¼ 1),
other fusions partners NR
Church et al.72 FISH 96% (25/26) IFS NTRK3
Croce et al.73 Targeted RNA MPS 54% (7/13) Uterine and vaginal sarcomas resembling fibrosarcoma 6 TPM3-NTRK1, 1 EML4-
NTRK3
Gatalica et al.51 Targeted RNA MPS 0.4% (2/478) 1 STS (poorly differentiated sarcoma with possible
myofibroblastic differentiation), 1 uterine sarcoma
(intermediate to high-grade sarcoma of uterine origin, with
myxoid stroma and no specific line of differentiation)
1 TPM3-NTRK1, 1 SPECC1L-
NTRK3
Rosen et al.60 Targeted RNA MPS 1% (11/944) Sarcoma NOS [9/770 (1%)], uterine sarcoma [2/174 (1%)] NR






Solomon et al.52 Targeted DNA and/
or
RNA MPS
0.7% (13/1915) IFS (n ¼ 2), lipofibromatosis-like neural tumor (n ¼ 2),
uterine sarcoma (n ¼ 2), uterine high-grade pleomorphic
sarcoma, high-grade spindle cell sarcoma, malignant spindle
cell sarcoma, spindle cell sarcoma, angiosarcoma, S-100
positivemalignant spindle cell neoplasm, low grade sarcoma
(all n ¼ 1)
LMNA-NTRK1 (n ¼ 4),
TPM3-NTRK1 (n ¼ 3), ETV6-




18% (3/17) IMT ETV6-NTRK3
Stransky et al.63 TCGA RNA-seq
dataset
1% (1/103) Sarcoma TPM3-NTRK1
Surrey et al.75 Targeted RNA MPS 4% (2/45) Sarcomas (other) 1 TFG-NTRK3, 1 RBPMS-
NTRK3
Suurmeijer et al.31 FISH, targeted RNA
MPS
60% (15/25) Malignant peripheral nerve sheath tumor-like 8 LMNA-NTRK1, 3 TPM3-
NTRK1, 1 SPECC1L-NTRK2,
1 TPR-NTRK1, 2 NTRK1 with
unknown fusion partners
Yamamoto et al.76 MPS (TBC), IHC 5% (2/40) IMT ETV6-NTRK3
Zhu et al.77 Targeted RNA MPS 3% (5/184) Lipofibromatosis-like neural tumor (n ¼ 2), IFS (n ¼ 1), IMT




GIST, gastrointestinal stromal tumor; IFS, infantile fibrosarcoma; IHC, immunohistochemistry; IMT, inflammatory myofibroblastic tumor; LPS, liposarcoma; MPS, massive parallel
sequencing; NOS, not otherwise specified; NR, not reported; RT-PCR, reverse transcription polymerase chain reaction; STS, soft tissue sarcoma; TCGA, The Cancer Genome Atlas.
Annals of Oncology G. D. Demetri et al.Larotrectinib has demonstrated robust efficacy in a
combined analysis of three phase I/II trials in adults and
children with TRK fusion cancers, irrespective of age or
tumor type.38 In an integrated dataset of 159 patients,
investigator-assessed objective response rate (ORR) was
79% [95% confidence interval (CI) 72% to 85%] and median
duration of response was 35.2 months (median follow-up
12.9 months). The median time to response was 1.8
months.39 Objective responses and durable disease control
were also observed in the subsets of patients with primary
CNS tumors or non-CNS solid tumors with brain metasta-
ses.40,41 Larotrectinib-related adverse events of grade 3-4
occurred in 13% of patients, and dose reductions and
treatment discontinuations due to treatment-related
adverse events occurred in 8% and 2% of patients,
respectively.39 Long-term follow-up is ongoing. The favor-
able safety profile of larotrectinib, together with robust
clinical efficacy, translated into rapid, sustained, and clini-
cally meaningful improvements in quality of life in the
majority of patients.421508 https://doi.org/10.1016/j.annonc.2020.08.2232Among the 17 different tumor types represented in the
larotrectinib dataset, the most common (47%) were sar-
comas.39 Of 71 patients with a sarcoma, two (3%) had an
osteosarcoma and a dedifferentiated chondrosarcoma, four
(6%) had a GIST, 29 (41%) had infantile fibrosarcoma, and 36
(51%) had other soft tissue tumors, including adult fibro-
sarcoma, inflammatory myofibroblastic tumor, infantile
myofibromatosis, lipofibromatosis, malignant peripheral
nerve sheath tumor, myopericytoma, spindle cell sarcoma,
high-grade endometrial stromal tumor, and synovial sar-
coma.43 The histologic subtypes of these patients were
captured as reported by the investigators; however, due to
the very rare nature of the subtypes reported and the
varied nomenclature used in sarcoma pathology, a central
pathology review and efficacy analysis by sarcoma subtype
is warranted. Furthermore, data on other driver alterations
in these patients would be informative.
The ORR with larotrectinib in adult and pediatric patients
with sarcoma harboring an NTRK fusion was 74% (95% CI
52% to 90%) and 94% (95% CI 82% to 99%), respectively.Volume 31 - Issue 11 - 2020
G. D. Demetri et al. Annals of OncologyObjective responses were observed in patients with soft
tissue sarcomas, GISTs, and infantile fibrosarcoma. Of two
patients with a bone sarcoma, one had a partial response
and one had stable disease. At a median follow-up of 15.6,
13.0, and 14.1 months, median duration of response,
progression-free survival, and overall survival were not
estimable (NE; range 1.6þ to 44.2þ), 28.3 (95% CI 16.8-NE),
and 44.4 (95% CI 44.4-NE) months, respectively (Table 2).
Grade 3-4 adverse events related to larotrectinib were re-
ported in 13% of patients.43Entrectinib
Entrectinib is a multi-targeted, pan-TRK, ROS1, and ALK in-
hibitor. It has low to sub-nanomolar enzymatic activity
against TRKA, TRKB, TRKC, ROS1, and ALK (IC50 values of 1.7,
0.1, 0.1, 0.2, and 1.6 nM, respectively).44 Entrectinib is FDA-
approved for use in adult and pediatric patients 12 years
of age with solid tumors harboring an NTRK gene fusion
who have disease that is metastatic or where surgery is
likely to result in severe morbidity, and who have pro-
gressed following treatment or have no satisfactory alter-
native therapy. Patients with a known resistance mutation
are not indicated for entrectinib treatment. Entrectinib is
also FDA-approved for patients with metastatic non-small
cell lung cancer (NSCLC) harboring a ROS1 gene fusion.45
Entrectinib demonstrated tumor-agnostic efficacy in an
integrated analysis of 54 patients with TRK fusion cancers in
one of three phase I/II trials. Independently assessed ORR
was 57% (95% CI 43% to 71%) and median duration of
response was 10.4 months (median follow-up 12.9 months).
Clinically meaningful and durable intracranial responses
were seen in patients with brain metastases. Adverse
events with entrectinib were mainly grade 1 or 2 and the
proportion of patients with dose reductions and treatment
discontinuations due to a treatment-related adverse event
was 27% and 4%, respectively.46
Among 13 patients with sarcoma in the overall entrecti-








87 (95% CI 77-94) 46 (95% CI 19-75)
Median duration of
response, months
NE (range 1.6þ to 44.2þ) 10.3 (95% CI 4.6-15.0)
Median progression-
free survival, months
28.3 (95% CI 16.8-NE) 11.0 (95% CI 6.5-15.7)
Median overall
survival, months
44.4 (95% CI 44.4-NE) 16.8 (95% CI 10.6-20.9)
CI, confidence interval; MPS, massive parallel sequencing; NE, not estimable; NTRK,
neurotrophic tyrosine receptor kinase receptor; PCR, polymerase chain reaction;
TRK, tropomyosin receptor kinase.
a In the larotrectinib clinical trials, NTRK gene fusions were detected by local MPS,
according to the procedures and analytic pipelines established by each laboratory, or
by FISH. All tests were carried out in a Clinical Laboratory Improvement
Amendments-certified (or equivalent) laboratory. In the entrectinib clinical trials,
NTRK gene fusions were detected by central RNA MPS (Trailblaze Pharos, Ignyta,
San Diego, CA, USA) or local molecular testing (FISH, quantitative PCR, or DNA or
RNA MPS).
Volume 31 - Issue 11 - 2020adenosarcoma, dedifferentiated chondrosarcoma, endo-
metrial stromal sarcoma, follicular dendritic cell sarcoma,
GIST, and malignant peripheral nerve sheath tumor. Of note,
there were no patients with infantile fibrosarcoma enrolled
in these trials. The ORR for the sarcoma subset was 46%.
Median duration of response, progression-free survival, and
overall survival were 10.3 (95% CI 4.6-15.0), 11.0 (95% CI
6.5-15.7), and 16.8 (95% CI 10.6-20.9) months, respectively
(Table 2).47
METHODS OF NTRK GENE FUSION TESTING
NTRK gene rearrangements and fusion transcripts can be
detected with different molecular pathology techniques
such as FISH, reverse transcription polymerase chain reac-
tion (RT-PCR), and massive parallel sequencing (MPS), while
TRK protein expression can be demonstrated by immuno-
histochemistry (IHC) (Table 3).48,49
Fluorescence in situ hybridization
FISH employs fluorescently labeled DNA probes that anneal
to specific regions within or flanking a gene(s) of interest. To
detect a particular NTRK gene fusion, colocalization of FISH
probes to each gene component of the fusion can be
demonstrated.27 In practice, however, it is more feasible to
use break-apart FISH probes that flank each of the three
NTRK genes and demonstrate rearrangement without
identifying the fusion partner gene.27,34 The efficient break-
apart approach avoids the need to develop an unrealistically
large number of FISH probe sets for uncommon fusions and
also detects novel fusions with as yet uncharacterized
fusion partners. FISH is available in many clinical labora-
tories, has a short turnaround time, and is relatively inex-
pensive; however, specific expertise is required to interpret
test results, particularly in paraffin sections where nuclear
slicing can result in artifacts. A false-negative rate of up to
30% has been reported with FISH in pediatric sarcomas.50
Furthermore, FISH does not distinguish between in-frame
and out-of-frame fusion events.
Immunohistochemistry
IHC typically employs an antibody that binds to antigens
common to the C-terminal domain of all three TRK proteins
(pan-TRK IHC) to detect elevated TRK protein expression
(Table 4). This method relies on the fact that most normal
cells express low levels of TRK while tumor cells harboring
an NTRK gene fusion typically display elevated TRK protein
levels. Nevertheless, TRKA, TRKB, and TRKC expression can
be observed by IHC in some normal cells: neurons, myen-
teric plexus, endothelial cells, and podocytes. In adult tis-
sue, expression is restricted to smooth muscle, testes, and
neuronal components. These components can be used as
internal (endothelial cells, myenteric plexus) or external
(podocytes in renal tissue) positive IHC controls. IHC rep-
resents a useful indirect readout for NTRK gene rear-
rangements. However, variable rates of sensitivity (75%-
88%) and specificity (81%-96%) have been reported,51,52
which may be explained by the use of differenthttps://doi.org/10.1016/j.annonc.2020.08.2232 1509
Table 3. Methods of NTRK gene fusion testing
FISH IHC RT-PCR MPS
Advantages Available in many clinical
laboratories
Widely available Widely available Allows simultaneous detection of
fusions between NTRK1e3 and any
number of known or novel fusion
partner genes
Rapid turnaround time Rapid turnaround time Rapid turnaround time
Relatively inexpensive Inexpensive Inexpensive
Allows identification of specific cell
types harboring the NTRK fusion
Disadvantages Requires specific expertise Detection of wild-type protein
expression, especially in tumors
with neural and myogenic
differentiation
Requires knowledge of fusion
partner gene sequence
Not routinely conducted in all
clinical laboratories
False negativity rate of 30% False negativity rate of w10%;
this rate may be higher in tumors
harboring NTRK3 fusions
Challenging to test for fusions
involving multiple NTRK and fusion
partner genes in parallel
Relatively long turnaround time
Does not distinguish between in-
frame and out-of-frame fusion
events
Relatively expensive
DNA MPS may miss NTRK2 and
NTRK3 fusions due to large introns
RNA MPS requires high quality RNA
Variable detection rates of different
panels
May identify non-oncogenic NTRK
rearrangements
MPS, massive parallel sequencing; NTRK, neurotrophic tyrosine receptor kinase receptor.
Annals of Oncology G. D. Demetri et al.antibodies, different IHC detection protocols, and poor or
excessive tissue fixation. Any of these variables can impact
IHC staining and intensity. The overall positive and negative
predictive values in one IHC study have been reported to be
11.2% and 99.8%, respectively (using pan-TRK antibody
clone EPR17341).51 Moreover, sensitivity has been shown to
vary according to the NTRK gene involved, with lower
sensitivity reported for NTRK3 (55%-79%) compared with
NTRK1 (88%-96%) and NTRK2 (89%-100%).51,52 A TRK IHC
signal should be considered as positive when staining of
1% of tumor cells is observed.53 Furthermore, the sub-
cellular pattern of pan-TRK IHC staining may indicate the
nature of the underlying gene fusion, with nuclear staining
suggestive of NTRK3 fusions and moderate to strong,
diffuse cytoplasmic staining suggestive of NTRK1/NTRK2
fusions.49,53,54
One benefit of IHC over molecular analyses is that it
provides evidence of the expression of the protein target of
TRK inhibitors. Of six patients with primary resistance toTable 4. Commercially available pan-TRK antibodies
Clone Company Label
EPR17341 Abcam RUO
EPR17341 (prediluted) Ventana CE/IVD
EPR18413 Abcam RUO
C17F1 Cell Signaling Technology RUO
A7H6R Cell Signaling Technology RUO
All antibodies are rabbit monoclonal and bind to the TRK C-terminal domain.
IVD, in vitro diagnostic; TRK, tropomyosin receptor kinase; RUO, research use only.
1510 https://doi.org/10.1016/j.annonc.2020.08.2232larotrectinib among the initial 55 patients treated in clinical
trials, three had tumor material available for central analysis
and in all three cases, pan-TRK IHC did not demonstrate
elevated TRK protein expression, indicating that the rear-
rangements detected by molecular testing did not yield
chimeric proteins with an intact TRK C-terminus in these
cases. One additional patient harbored an NTRK3 kinase
domain mutation that conferred resistance.38
IHC is widely available in clinical laboratories, allows a
rapid turnaround time, and is far less expensive than FISH.
Although more data on sensitivity and specificity are
needed, pan-TRK IHC is considered to have a false-negative
rate ofw10%.52 In a study of seven patients with soft tissue
spindle cell tumors and NTRK3 rearrangement detected by
both IHC and FISH, rearrangements were only confirmed by
RNA sequencing in three cases.30 Therefore, sarcomas with
a high probability of harboring an NTRK fusion but with
negative pan-TRK IHC staining should be considered for
confirmatory testing with a genomic method (FISH or MPS).Studies
Hechtman et al.78 Leica Bond 3 (ER2 retrieval, dilution 6 mg/ml)
Solomon et al.52 Leica Bond 3 (ER2 retrieval, dilution 6 mg/ml)
Gatalica et al.51 Ventana Benchmark or Dako Autostainer
Rudzinski et al.79 Ventana Benchmark (CC1 retrieval, 1:500 dilution)
Hung et al.80 Manual (1/300 dilution)
Xu et al.81 Leica Bond 3
Feng et al.82 Ventana assay on dedicated platform
Not reported
Murphy et al.83 Dako Autostainer (dilution 1:25, cocktail with
anti-ALK and anti-ROS1 antibodies)
Not reported
Volume 31 - Issue 11 - 2020
G. D. Demetri et al. Annals of OncologyIHC may prove to be a valuable screening tool to highlight
NTRK rearrangements, with the exception of CNS and
neuroendocrine tumors where IHC is not a reliable
screening tool because of endogenous elevated TRK
expression. Furthermore, many sarcomas with myogenic or
neural differentiation may display focal TRK expression.53
Thus, in these tumors, only diffuse staining should be
considered positive. Strong TRK IHC staining can also be
found in cases with NTRK gene amplification, supporting the
requirement to confirm the presence of NTRK rearrange-
ments with an orthogonal molecular method (Figure 1).30A B
C D
Figure 1. Examples of positive TRK IHC staining.
(A) ETV6-NTRK3 fusion infantile fibrosarcoma stained by hematoxylin and eosin an
detection. (C) Focal staining in a leiomyosarcoma without NTRK gene alterations. (D)
IHC, immunohistochemistry; NTRK, neurotrophic tyrosine receptor kinase receptor; T
Volume 31 - Issue 11 - 2020Reverse transcription polymerase chain reaction
RT-PCR uses primers flanking the breakpoint region in the
transcript encoded by the fused genes, with the 30 primer
annealing to an NTRK gene and the more 50 primer
annealing to the relevant fusion partner gene. When pre-
sent in the tumor, the targeted portion of the fusion tran-
script will be amplified yielding a positive RT-PCR result.
RT-PCR is a widely established technique and is rapid and
inexpensive. Multiplex RT-PCR can be carried out using
primer sets specific to a number of known NTRK fusion
genes in a single assay. However, this method does notd (B) pan-TRK IHC with A7H6R clone (Cell Signaling Technology) and ultraView
Intense staining in a leiomyosarcoma with NTRK1 copy number gain.
RK, tropomyosin receptor kinase.
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thus, a negative RT-PCR result cannot exclude the presence
of a fusion. Therefore, RT-PCR is only recommended in
settings where a specific type of fusion is expected
following histologic-based triage, for instance, ETV6-NTRK3
in infantile fibrosarcoma, or as a complementary method
for gene rearrangements detected by FISH.Massive parallel sequencing
MPS allows for the simultaneous detection of fusions be-
tween NTRK1e3 and any number of fusion partner genes,
depending upon the particular assay used. Targeted MPS
with a panel of primers that hybridize to select regions in
predefined genes is the preferred method. DNA-based MPS
assays are not the best approach for identifying all NTRK
fusions, especially those involving the NTRK2 and NTRK3
genes because of their large introns. Targeted RNA MPS
allows for more systematic detection of NTRK fusion tran-
scripts. Adequately designed targeted RNA MPS panels
allow for the detection of novel NTRK gene fusion partners,
and there are a number of commercially available assays
that cover all three NTRK genes. However, it should be
noted that different commercial panels have shown some
remarkable differences in detection rate.55 MPS is not
routinely conducted in all clinical laboratories, has a rela-
tively long turnaround time, and is quite expensive,
particularly if only a limited number of tests are required.
However, various groups are continuing to develop RNA
MPS platforms that can detect in parallel the multitude of
fusion genes observed in sarcomas.
In addition to functional NTRK fusion transcripts, RNA-
based MPS assays may identify non-oncogenic aberrant
NTRK rearrangements (incidental genomic alterations) that
do not yield constitutively active fusion proteins. Clinicians
should be aware of this possibility and understand how to
interpret complex MPS data reports. If expression of the
fusion protein is in doubt, IHC may be a useful confirmatory
tool. Similarly, NTRK point mutations occur more often than
gene fusions and may also be identified by MPS assays;
however, these mutations are not considered predictive of
treatment response.56
TESTING FOR NTRK GENE FUSIONS IN SARCOMAS
Given the robust efficacy and favorable safety profiles of
TRK inhibitors demonstrated in patients with TRK fusion
sarcomas, testing for NTRK gene fusions should be incor-
porated into the clinical management of patients with sar-
coma, with prioritization in specific stages and subtypes, as
discussed below. The rarity of these oncogenic drivers
presents a number of challenges, including the cost of
testing, limited resources, limited tumor tissue, and the
complexities of integrating a new molecular test into the
current diagnostic workup. However, the overall benefit of
molecular testing in the diagnosis and clinical management
of patients with sarcoma has been demonstrated in large
multicenter studies, similar to what has been shown for
lung cancer.57,58 While sequence-based testing methods1512 https://doi.org/10.1016/j.annonc.2020.08.2232(RNA MPS or RT-PCR) are recommended for the detection
of productive NTRK gene rearrangements, IHC with a vali-
dated antibody against TRK proteins (most easily with a
pan-TRK antibody) may be used as a fast and less expensive
pre-screening tool. Furthermore, selecting histotypes
negative for pathognomonic genetic alterations (other
translocations, kinase mutations, MDM2/CDK4 amplifica-
tion) could allow exclusion of w45% of all sarcomas from
NTRK gene fusion testing, given the mutual exclusivity of
such driver alterations.59,60
NTRK fusion testing may be prioritized in disease settings
where TRK inhibitor therapy is most relevant, also consid-
ering that some of the recently reported NTRK-rearranged
entities tend to behave indolently. The majority of sarcoma
patients are diagnosed while still localized and these tumors
are amenable to curative surgical resection without the
need for systemic therapy. Therefore, NTRK fusion testing in
primary, resectable sarcomas may not be necessary (except
when used for definitive diagnosis, such as in the case of
putative infantile fibrosarcomas). Nevertheless, for patients
at high risk of relapse, NTRK gene fusion testing might
provide clinically actionable information for later in the
disease course. Testing for NTRK gene fusions should be
carried out in patients with locally advanced, unresectable
tumors or in those with metastatic disease failing conven-
tional therapies.
Sarcomas with a high NTRK fusion frequency (priority 1)
Given the potential cost and resource limitations of uni-
versal testing, we propose a three-tiered diagnostic algo-
rithm for the prioritization of NTRK gene fusion testing
according to the likelihood of finding a fusion (Figure 2). The
highest priority for NTRK fusion testing is given to the his-
tologic subtypes that commonly or non-infrequently harbor
NTRK gene fusions, such as infantile fibrosarcomas61 and
ALK and ROS1 fusion-negative inflammatory myofibroblastic
tumors.62 These entities should be tested upfront for NTRK
fusions in all situations53 and the test should ideally be
ordered by the pathologist following central pathologic
diagnosis. In fact, NTRK fusion testing is often conducted as
part of the diagnostic process for suspected infantile fi-
brosarcomas. For histologic subtypes with a high pre-test
probability of harboring an NTRK fusion, we recommend
the use of FISH, IHC, or MPS. A negative FISH result should
be confirmed by MPS. For a positive FISH result, confir-
mation that the fusion is in-frame by MPS or RT-PCR should
be considered in parallel to treatment. MPS confirmation of
a negative IHC result is recommended for cases with typical
histology. For cases with positive IHC results, treatment may
be considered concurrently with confirmatory MPS.
Sarcomas with a low NTRK fusion frequency (priority 2)
NTRK gene fusions are thought essentially to be mutually
exclusive to other primary oncogenic drivers.59 In a study of
patients with various tumor types, 31% of NTRK fusion-
negative cases harbored activating MAPK pathway alter-
ations compared with only 1.5% (n ¼ 1) of NTRK fusion-Volume 31 - Issue 11 - 2020
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Figure 2. Recommended algorithm for NTRK gene fusion testing in sarcomas.
GIST, gastrointestinal stromal tumor; IFS, infantile fibrosarcoma; IHC, immunohistochemistry; IMT, inflammatory myofibroblastic tumor; LPS, liposarcoma; MPS, massive
parallel sequencing; NTRK, neurotrophic tyrosine receptor kinase; RT-PCR, reverse transcription polymerase chain reaction; TRK, tropomyosin receptor kinase.
a For patients at high risk of relapse, NTRK gene fusion testing might provide clinically actionable information for later in the disease course.
b If histology is typical then confirmation by MPS is recommended.
c Treatment may be considered concurrently with confirmatory MPS.
d Consider parallel validation by MPS or RT-PCR to confirm that fusion is in-frame.
e Avoid IHC screening in cases with myogenic and neural differentiation due to the high rate of false positivity.
G. D. Demetri et al. Annals of Oncologypositive cases.60 In another study, among 103 sarcomas
tested for recurrent kinase fusions in one study, one sample
had an NTRK1 gene fusion but no other concurrent fu-
sions.63 Therefore, for sarcoma subtypes where NTRK gene
fusions are rare, NTRK fusion screening should only be
routinely done in cases already known to lack canonical
oncogene alterations, such as wild-type GISTs and sarcomas
with complex genomics. Sarcomas with recurrent gene fu-
sions, GISTs with KIT, PDGFR, SDH, NF1, or BRAF alterations,
and liposarcomas withMDM2 or CDK4 amplification may be
excluded from routine NTRK fusion testing. Of this subset,Volume 31 - Issue 11 - 2020however, tumors that do not show specific lineage differ-
entiation (i.e. positive only for vimentin) may be enriched in
molecular alterations including NTRK fusions.Sarcomas with canonical oncogene alterations (priority 3)
Very infrequent situations of NTRK gene fusions co-
occurring with other driver alterations in untreated
tumors have been reported; however, the NTRK fusion ap-
pears to exert oncogenic dominance in these rare cases.59,60
Therefore, NTRK fusion testing in tumors with canonicalhttps://doi.org/10.1016/j.annonc.2020.08.2232 1513
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context in order to provide data on frequency and clinical
significance of co-occurring NTRK gene fusions. While NTRK
gene fusions have been identified in a range of sarcoma
subtypes (Table 1), comprehensive data on NTRK fusion
frequency in different sarcoma subtypes are lacking.
Therefore, the majority of soft tissue and bone sarcomas
should continue to be studied until there are sufficient data
to guide future diagnostic approaches. Comprehensive data
about NTRK gene fusion frequency in different sarcoma
subtypes and correlation with morphological features
would better inform the optimal approach to NTRK gene
fusion screening in sarcomas and should be collected. In
this regard, a prospective registry and retrospective collec-
tion of TRK fusion sarcoma cases would be valuable and a
study is planned in Spain and France where all soft tissue
sarcomas will be prospectively screened with pan-TRK IHC,
with positive cases then confirmed by MPS.CLINICAL MANAGEMENT OF TRK FUSION SARCOMAS
The labeled indications for larotrectinib (FDA and EMA) and
entrectinib (FDA) include patients for whom surgery is likely
to result in severe morbidity or who have no satisfactory
alternative therapy. Therefore, the advantages and disad-
vantages of TRK inhibitors compared with other available
therapies should be discussed by the patient and the
treating physician.
In addition to the overall efficacy of TRK inhibitors
described earlier (Table 2), efficacy of neoadjuvant laro-
trectinib therapy has also been demonstrated in situations
where surgery would otherwise result in life-changing op-
erations (e.g. amputation). Five children with locally
advanced TRK fusion sarcomas (three with infantile fibro-
sarcomas and two with other soft tissue sarcomas) achieved
a partial response to neoadjuvant larotrectinib and under-
went resection after a median of six treatment cycles. Re-
sections were R0 (negative resection margins with no tumor
at the inked resection margin) in three patients, R1
(microscopic residual tumor at the resection margin) in one
patient and R2 (incomplete resection with macroscopic re-
sidual tumor) in one patient. Three patients achieved
complete or near-complete pathological responses and at
last follow-up remained disease-free 7-15 months after
surgery.64 While these data are encouraging, the question
of if and when to discontinue TRK inhibitor therapy
following a complete response still remains.
For patients with metastatic disease requiring systemic
therapy, treatment with larotrectinib or entrectinib is
approved after failure of standard therapies and may be
valuable after standard first-line treatment given the rapid,
durable responses and tolerability observed. In clinical trials
of larotrectinib and entrectinib, responses were typically
observed at the time of the first protocol-mandated tumor
assessment, and pseudo-progression is uncommon with
these therapies; therefore, it may be possible to quickly
evaluate treatment response. However, it should be noted
that no data exist for larotrectinib or entrectinib compared1514 https://doi.org/10.1016/j.annonc.2020.08.2232or combined with standard systemic cytotoxic therapies.
Furthermore, the long-term safety profile of TRK inhibitors
remains unknown and requires further study.
NTRK gene fusions have been shown to persist in tumors
over time,60 suggesting that they remain the dominant
oncogenic driver over the course of different treatments.
This provides the rationale for a sequential TRK inhibitor
treatment approach in patients with TRK fusion cancer,
similar to current practice in oncogene-addicted (e.g. EGFR,
ALK) NSCLC. The next-generation TRK inhibitors selitrectinib
and repotrectinib have shown encouraging activity in pa-
tients who had progressed on larotrectinib or entrectinib
due to acquired resistance mutations in the TRK kinase
domain, including patients with sarcoma.65-67
SUMMARY
The emergence of NTRK gene fusions as clinically actionable
biomarkers marks a new era in precision oncology, with the
tumor-agnostic approvals of larotrectinib and entrectinib
representing milestones in drug development. TRK in-
hibitors provide new personalized treatment options with
the potential to extend survival and improve quality of life
in some patients with sarcoma harboring NTRK gene fu-
sions. Integrating NTRK fusion testing into the current
diagnostic workup of patients with sarcoma is particularly
challenging due to the rarity of this biomarker. Here, we
propose a diagnostic strategy to address this that considers
disease stage and histologic and molecular subtypes to
facilitate routine testing for TRK expression and subsequent
testing for NTRK gene fusions.
Routine genome-wide MPS in sarcomas may not
currently be cost-effective due to the small number of
additional genomic alterations to be tested. However, IHC
provides a valuable pre-screening tool and focused MPS
panels, such as those that detect NTRK gene fusions and
other key gene fusions in parallel, are particularly relevant
for sarcomas. Further research is necessary to fully establish
the sensitivity and specificity of pan-TRK IHC. Furthermore,
multinational comparative studies are encouraged to in-
crease the reproducibility of MPS assays. Finally, prospec-
tive studies will be essential to determine the frequency of
NTRK gene fusions in different sarcoma subtypes and cor-
relation with morphological, biological, and clinical features
in order to better inform the optimal approach to NTRK
gene fusion screening.
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